June 15, 2026: Colorado becomes the second state given federal approval for Canadian drug importation program
Major Stories
The FDA has approved Colorado’s Section 804 Canadian drug importation program, making it the second state to receive approval. While it’s often touted as a solution to lowering prescription drug costs in the US, logistical hurdles have plagued similar programs. Canadian residents and officials have raised concerns that large-scale drug exports to the U.S. could worsen Canada’s own medication shortages. American critics of importation programs also argue that drugs sourced outside the U.S. supply chain may be more difficult to track through the FDA’s established track and trace systems, which took over 10 years to establish, potentially increasing the risk of counterfeit or compromised products entering the market.
A similar program was established in Florida in 2019, which has cost the state $132 million while never importing a single unit of medicine. In our statement on the approval, PSM Executive Director Shabbir Imber Safder said, “Colorado’s program will not result in lower cost medicines for its residents but could drain funds from the state’s coffers, ultimately doing a disservice to all Coloradans. It’s a losing proposition at a time when consumers deserve better.”
Domestic
New analysis of the social media-driven peptide black market. Iowa regulators charge a mail-order compounding pharmacy. 26-year sentence for running a dark web drug marketplace.
Chainalysis graph comparing the buyer purity testing spend to total purity testing lab growth by era of the peptide market.
A new report from blockchain analytics firm Chainalysis found that the cryptocurrency-powered gray-market peptide industry has grown into a more than $100 million annual market, driven in part by social media popularization. The report links some overseas peptide suppliers to Chinese chemical manufacturers that previously sold fentanyl and amphetamine precursors, arguing that these firms have pivoted to peptides as law enforcement scrutiny of the illicit drug trade increased. Chainalysis also found that independent product testing has declined sharply as the market expanded, raising concerns about the reliance on vendor-provided purity reports, and growth has been fueled by demand for lower-cost alternatives to prescription weight loss drugs, particularly among younger consumers influenced by the online “looksmaxxing” trend.
As AI-generated content and online health influencers continue to gain traction, experts are urging consumers to rely on qualified medical professionals rather than social media for healthcare advice. Dr. Brian Druker, the renowned cancer researcher whose work helped transform leukemia treatment, told The Oregonian that scammers have been using his name and image to promote ivermectin as a cancer cure. “I spent an entire career based on honesty, integrity, bringing new treatments to patients that are going to improve their outcomes,” Druker told the outlet. “For somebody to be able to usurp that and undermine the trust that people have in me is really disturbing.” Researchers warn that physician impersonation is becoming more common, potentially misleading vulnerable patients, eroding trust in legitimate medical experts, and promoting unproven treatments.
A California man was sentenced to more than 26 years in federal prison for selling methamphetamine and fentanyl through the dark web marketplace Nemesis Market. Prosecutors said he distributed drugs nationwide, including multiple sales to undercover agents, before his arrest in 2023. The case was part of a broader federal investigation that led to the 2024 shutdown of Nemesis Market, which processed more than 400,000 orders of drugs, including thousands involving fentanyl and other opioids.
Iowa regulators have filed charges against a Florida-based pharmacy group, alleging the mail-order compounding pharmacy failed to meet federal standards for preparing sterile and nonsterile compounded medications and did not consistently provide required patient counseling, according to the Iowa Capital Dispatch. The action follows disciplinary measures in Kansas, Louisiana, and Ohio, where the company faced fines and licensing sanctions related to pharmacy practice violations and the distribution of compounded drugs. The group, which operates in 42 states, has not publicly responded to the Iowa allegations.
An NBC Bay Area investigation highlighted whistleblower allegations and state regulatory findings involving Aequita Pharmacy, a Washington-based supplier that partnered with telehealth company Mochi Health to provide compounded GLP-1 weight-loss medications. Washington health regulators said they substantiated complaints that included the use of unlicensed workers, improper compounding practices, and other quality-control concerns, ultimately issuing a notice that the pharmacy's operations posed a risk of serious harm. Aequita closed in April 2025, while Mochi Health continues to offer compounded GLP-1 medications through other pharmacy partners.
Andrea Thomas, founder of Facing Fentanyl and co-founder of ARMOUR Families, received the Excellence in Education Award at the 2026 Education 2.0 Conference in Las Vegas. The award recognized her work in fentanyl prevention education, public awareness, and community engagement following the loss of her daughter to fentanyl poisoning in 2018. Thomas has become a national advocate for fact-based drug education and is the founder of National Fentanyl Prevention and Awareness Day.
The European Medical Journal reported on the steps the FDA is taking in its crackdown on compounded weight loss drugs, including warning letters and selling restrictions. EMJ quoted PSM Executive Director Shabbir Imber Safdar, who said, “Compounders operate on the outskirts of drug safety regulations and don’t face the same stringent requirements.”
Pill Presses
An Ohio man who operated a home day care was sentenced to 12 years in federal prison after admitting to manufacturing and distributing fentanyl- and methamphetamine-laced pills. Federal investigators discovered industrial-sized pill presses, thousands of counterfeit pills, and large quantities of fentanyl and methamphetamine at a warehouse linked to the operation. Authorities also found drugs and firearms at his residence, including a loaded handgun hidden inside a children's toy toolbox.
Kaff News reports that authorities in Arizona disrupted a fentanyl trafficking operation following a multi-agency investigation that began in April after a traffic stop uncovered over a pound of fentanyl. Officers executed a search warrant at a property tied to the defendant, where they found evidence of narcotics manufacturing, including an industrial-sized pill press, pill dyes, cutting agents, and methamphetamine.
Regulators protecting patients in the news
The FDA issued a warning letter to a Massachusetts sterile IV bag manufacturer after an inspection found serious manufacturing violations, including improper aseptic practices, inadequate environmental monitoring, and failures in contamination control that put patients at risk. The agency also identified deficiencies in quality oversight, investigation of product issues, and facility maintenance, along with concerns about continued use of potentially defective IV bag components.
The FDA issued a warning letter to a Chinese API manufacturer after an inspection found serious violations, including poorly maintained, contaminated, and reactive equipment surfaces that could compromise drug quality. The agency also determined that the company’s quality unit lacked adequate oversight and failed to ensure proper facility maintenance and equipment suitability.
The FDA also issued a warning letter to another Chinese manufacturer following an inspection that found inadequate testing of finished drug products and raw materials, weak quality control systems, and a lack of process validation and stability data. The agency also found that the firm’s OTC pain-relief products were unapproved new drugs and misbranded due to noncompliant ingredients and unsupported health claims.
The FDA issued a warning letter to 8 OTC product manufacturers and one prescription drug manufacturer after finding failures to properly test talc components for identity and asbestos contamination risks in drug products. The agency also cited weak quality unit oversight, inadequate testing standards, and reliance on insufficient supplier data without proper validation in many of the letters.
International
Australia cracks down on unapproved peptides. The EU warns of synthetic opioids in counterfeit drugs. Malta warns against experimental retatrutide.
Australia’s Therapeutic Goods Administration has launched a crackdown on unapproved peptides, citing rising imports, online sales, and safety risks linked to their growing popularity in fitness and beauty markets, according to ABC News. Officials warn these substances have not been assessed for safety or quality and have been associated with serious adverse effects, including hospitalizations and potential long-term health risks. The agency’s enforcement response may include seizures, fines, and criminal penalties as authorities aim to disrupt illegal supply chains and reduce consumer harm.
Politico announced that the EU Drugs Agency warns that dangerous synthetic opioids, including highly potent substances like nitazenes, are increasingly appearing in fake medicines across Europe and are driving a rise in overdose deaths. Officials say these drugs are often far more potent than heroin or fentanyl and are spreading faster than public health systems can respond.
Health authorities in Malta have warned against unauthorized products claiming to contain the weight-loss drug retatrutide, which is being sold online and through social media without approval. The Times of Malta reports that officials say the substance is unregulated and may be counterfeit or unsafe, with potential risks including contamination, adverse reactions, and other serious health effects. They are urging the public to only use medicines from licensed pharmacies and report suspicious products.